O neuroblastoma é o tumor sólido extra-cranial mais comum e mortal da infância, sendo o tempo de sobrevida nos casos mais agressivos ainda muito curto. Uma das esperanças nesses casos é que os estudos moleculares possam fornecer informações sobre os genes ou as vias moleculares que governam a patogênese dos neuroblastomas. Pois, há poucos genes como o MYCN, que foi descrito por estar diretamente ligado ao neuroblastoma. A amplificação deste oncogene ocorre em pouco mais de 25% dos neuroblastomas e é considerada como o mais importante marcador de prognóstico nestes tumores, sendo fortemente relacionada aos estádios avançados da doença e falha no tratamento. Outros genes do amplicon do MYCN, incluindo o DDX1 \"DEAD box polypeptide 1 gene\" e o NAG \"neuroblastoma-amplified gene\", estão sendo observados por se apresentarem co-amplificados com o MYCN. Entretanto, a importância deste fenômeno no prognóstico ainda é desconhecida. Os objetivos deste trabalho foram determinar qual o melhor método para estudar a amplificação dos genes MYCN, DDX1 e NAG, além de esclarecer a importância da coamplificação dos genes DDX1 e NAG no prognóstico. Procedimento: O número de cópias dos genes MYCN, DDX1 e NAG foi determinado por PCR em Tempo Real e PCR convencional em 100 neuroblastomas primários. Os dados da PCR em Tempo Real foram analisados por quantificação absoluta e relativa. Os resultados da PCR convencional foram analisados por eletroforese em gel de agarose, medindo a intensidade das bandas formadas no gel no sistema Kodak. A relevância da amplificação gênica como marcador de prognóstico foi avaliada em 74 pacientes, dos quais nós obtivemos o acompanhamento clínico. Resultados: Nos 74 casos estudados, ambos os métodos demonstraram que a amplificação do MYCN estava associada com os estádios mais avançados da doença. A análise das curvas de sobrevida livre de progressão confirmou que pacientes com ausência de amplificação do MYCN apresentavam maior tempo de sobrevida. Nós também analisamos a amplificação do DDX1 nas mesmas amostras incluindo aquelas com ausência de amplificação de MYCN. Não foi encontrada nenhuma relação entre a co-amplificação com idade ao diagnóstico ou tempo de sobrevida. Conclusões: Os métodos aplicados para calcular o número de cópias dos genes na PCR em Tempo Real mostraram-se equivalentes. A PCR em Tempo Real apresentou maior acurácia nos resultados quando comparada à PCR convencional. A análise da sobrevida não demonstrou relação entre a amplificação dos genes DDX1 e/ou NAG com piora no prognóstico. / Neuroblastoma is the most common and deadly extra-cranial solid childhood tumor. Survival rates for aggressive neuroblastomas are still disappointingly low. One of the hopes is that molecular studies will provide insights into the genes and molecular pathways that govern neuroblastoma pathogenesis. However, at present only a few genes as MYCN have been directly linked to neuroblastoma. MYCN oncogene amplification, occurring in up to 25% of neuroblastomas, has been considered the most important prognostic factor, strongly correlating to advanced stage disease and treatment failure. Another genes in the MYCN amplicon, including the DEAD box polypeptide 1 (DDX1) gene, and neuroblastoma-amplified gene (NAG gene), have been found to be frequently co-amplified with MYCN in NB. But the prognostic significance of the coamplification remains unclear. The aims of this study were to evaluate which is the best method to study the gene amplification of those three genes MYCN, DDX1 and NAG, as well as clarify the prognostic significance of the co-amplification or DDX1 and NAG with MYCN. Procedure: The gene copy numbers of MYCN, DDX1, and NAG were determined by the real-time quantitative polymerase chain reaction and conventional polymerase chain reaction in 100 primary NBs. Real-Time data were analyzed by absolute and relative quantification. For conventional PCR, samples were electrophoresed on a 2% agarose gel and the intensity of each band evaluated by Kodak image software. To evaluate of the prognostic significance of the gene amplification we had only 74 cases in witch we could analyze the follow-up. Results: In all 74 cases, both methods demonstrated that MYCN amplification was associated mainly with advanced cancer stages, and the analysis of overall survival confirmed that patients without MYCN amplification had a cumulative survival significantly higher than patients with oncogene amplification. We also studied DDX1 and NAG amplification for all NB samples even that without MYCN amplification. No relationship between any gene co-amplification status and disease stage, age at diagnosis, or overall survival was found. Conclusions: The two methods used to calculate gene copy number for Real Time PCR assay shown to be equivalent. Real Time PCR assay shown to be more accurate to study gene amplification than conventional PCR assay. Survival analysis pointed out that DDX1 and/or NAG amplification has no additional adverse effect on prognosis.

Les modèles animaux actuellement disponibles pour l’étude des leucémies humaines ne sont pas adaptés pour le développement optimal de nouvelles thérapies ciblées. Au cours de ce projet, qui s’inscrit dans une double perspective fondamentale et industrielle, nous avons cherché à générer un modèle versatile de leucémogénèse humaine chez la souris humanisée BRGS (BALB/c Rag2-/- IL-2Rγc-/- SIRPα.NOD). Les animaux sont greffés avec des progéniteurs hématopoïétiques transduits par des vecteurs lentiviraux surexprimant les oncogènes MYC et BCL2 et placés sous le contrôle d’un promoteur ubiquitaire (EF1α ou SFFV). Le suivi longitudinal des animaux sur une période de 5 mois montre que seule la construction SFFV/Myc-T2A-Bcl2 entraîne la transformation des progéniteurs hématopoïétiques. Entre 12 à 14 semaines post-greffe, >90% des animaux développent des lympho-proliférations de type pro-B (CD19+CD10+CD9+CD20-cytIgM-) infiltrant principalement la rate et la moelle osseuse, et circulant en abondance dans le sang. Le caractère transmissible des tumeurs est validé par des greffes secondaires de tumeurs spléniques. Les cultures in vitro de progéniteurs hématopoïétiques suggèrent que l’émergence des blastes est liée à la réactivation d’un programme B latent dans les précurseurs T, dont le développement est bloqué. Nous avons développé en parallèle un modèle de tumeur autologue. L’ensemble de ces résultats valide le modèle de leucémogénèse humaine développé chez la souris humanisée BRGS et ouvre des perspectives pour la caractérisation fonctionnelle des mécanismes de leucémogénèse, et la validation préclinique de nouvelles stratégies anti-tumorales. / Existing animal models for the study of human leukemia are not accurate for the proper development of innovative, targeted therapies. The aim of this project, which contains both a fundamental and an industrial perspective, therefore was to develop a new, versatile model of human leukemogenesis in the BRGS (BALB/c Rag2-/- IL-2Rγc-/- SIRPα.NOD) humanized mouse. Animals are grafted with hematopoietic progenitors transduced with lentivirals vectors to allow overexpression of MYC and BCL2 proteins under the control of an ubiquitous promotor (EF1α or SFFV). Longitudinal monitoring of the animals over five months shows that only the SFFV/Myc-T2A-Bcl2 construction induces the transformation of humans hematopoietics progenitors. Between 12 and 14 weeks post-transplantation, more than 90% of the animals develop pro-B lympho-proliferations (CD19+CD10+CD9+CD20-cytIgM-), with tumor cells being mainly found in the spleen, the bone marrow and in blood. Tumor transferability is achievable through secondary transplantation in immunodeficient mouse recipients. In vitro culture of bone marrow T cell progenitors suggest that the blasts arise from these cells after reactivation of a latent B cell program with blockade of their T cell development. In parallel, we have also developed an autologous tumor model. Altogether, these results validate the human leukemogenesis model constructed here in humanized BRGS mice and provide attractive prospects regarding the functional characterization of leukemogenesis and a preclinical validation of new anti-tumor strategies.

c-MYC est un facteur de transcription oncogénique dont l’expression est dérégulée dans 78% des gliomes. On observe d’ailleurs une corrélation positive entre sa surexpression et le grade des gliomes. De plus, cette surexpression serait essentielle à la survie des cellules souches tumorales, cellules qui seraient davantage résistantes à la chimiothérapie et à la radiothérapie en plus d’avoir un caractère plus invasif. Il a aussi été démontré que l’inhibition de c-MYC par ARN interférents peut sensibiliser les cellules cancéreuses à l’apoptose et réduire leur prolifération. Sa surexpression relative dans les glioblastomes (GBM) est signe de la malignité et l’espérance de vie des patients atteints par ces tumeurs est réduite chez les patients plus âgés. c-MYC doit s’hétérodimériser avec MAX, son partenaire obligatoire afin de se lier aux promoteurs de ses gènes cibles contenant des EBox (CANNTG) et ainsi activer leur transcription. Cependant, il a été proposé que MAX pourrait homodimériser et agir comme antagoniste en compétitionnant pour les mêmes sites de reconnaissance que l’hétérodimère c-MYC/MAX sur l’ADN. Notre étude vise donc à évaluer l’effet dose-dépendant d’un traitement exogène de MAX*WT, correspondant à une version tronquée du facteur de transcription MAX, sur différentes lignées cellulaires de GBM. Nous avons d’abord étudié les capacités de la protéine à transloquer dans les cellules par microscopie. Ceci a permis de déterminer que le peptide s’internalise rapidement (15 minutes) pour ensuite s’accumuler au niveau nucléaire (24 h, 48 h). Par la suite, des analyses de FACScan ont démonté qu’un traitement de 72 heures provoque une inhibition de la prolifération cellulaire. À l’aide de chambres de Boyden et d’essais de croissance en sphéroïdes dans une matrice de Matrigel(indice supérieur TM]), nous avons observé une diminution importante du caractère invasif des lignées de gliomes malins suite au traitement avec MAX*WT. Ces résultats démontrent que la protéine MAX*WT semble avoir un effet antinéoplasique sur plusieurs lignées de gliomes malins et que la voie de signalisation de c-MYC pourrait constituer une cible thérapeutique intéressante.

Dans le monde actuel, il demeure encore que le cancer colorectal soit une des premières causes de mortalité par cancer. Le développement et la progression de ce cancer fait intervenir des événements complexes comme les mutations oncogéniques mais aussi la surexpression de différents récepteurs membranaires dont les intégrines. Dans l'intestin grêle, l'intégrine α1β1 est exprimée uniquement par les cellules prolifératives de la crypte. Ce profil supporte le rôle rapporté pour cette intégrine dans le recrutement de la cavéoline-1 et l’activation en aval, via Shc, de la voie proliférative Ras/ERK dans les fibroblastes. L’expression de la sous-unité α1 n’a pas été décrite dans le tissu colique normal et tumoral. Chez la souris, l'intégrine α1β1 soutient la motilité des cellules tumorales mammaires et, de concert avec le facteur oncogénique Kras, elle potentialise la croissance et l’invasion tumorales. Ces rôles ne sont pas connus dans le cancer colorectal. L’objectif dans cette étude est d’analyser l’expression de la sous-unité α1 dans le cancer colorectal, de définir les facteurs de régulation de son expression et d’identifier les rôles de l’intégrine α1β1 dans la progression du cancer colorectal. Mes expériences de recherche ont permis de montrer que la sous-unité α1 est présente dans 65% des adénocarcinomes colorectaux et que son expression est observée non seulement dans les cellules épithéliales mais aussi dans les cellules du microenvironnement de la tumeur. Mes résultats ont contribué à l’identification de la sous-unité α1 comme une nouvelle cible directe de l’oncogène MYC dans le cancer colorectal. J’ai démontré que MYC se lie directement au promoteur du gène ITGA1 au niveau de deux éléments de réponse spécifiques. Ce contrôle s’est reflété par une corrélation significative entre l’expression des deux protéines MYC et α1 dans 72% des adénocarcinomes étudiés. J’ai pu également montrer pour la première fois que l’intégrine α1β1 est importante pour la prolifération des cellules tumorales colorectales ainsi que pour leur migration et leur survie. De plus, en utilisant des modèles de xénogreffes, j’ai observé que cette intégrine est importante pour la croissance des tumeurs colorectales, et son absence induit également une importante nécrose tumorale. Mes découvertes apportent de nouvelles connaissances dans la compréhension de l’implication de l’intégrine α1β1 dans la carcinogenèse colorectale. Cette intégrine pourrait représenter une cible thérapeutique intéressante dans le traitement du cancer colorectal.

In this dissertation, we explore the transcriptional regulatory roles of Gquadruplex- forming motifs and the involvement of specific transcriptional factors, which interact with the same elements, in the control of human c-myc and bcl-2 gene expression. The G-quadruplex structures within the NHE III1 region of the c-myc promoter and their ability to repress transcription has been well established. However, a longstanding unanswered question is how these stable DNA secondary structures are transformed to activate c-myc transcription. NDPK-B has been recognized as an activator of c-myc transcription via interactions with NHE III1 region of the c-myc gene promoter. Through the use of RNAi, we confirmed the transcriptional regulatory role of NDPK-B. We demonstrate that NDPK-B has DNA binding activity and the nuclease activity results from a contaminating protein. NDPK-B preferentially binds to the singlestranded guanine-rich strand of the c-myc NHE III₁. Potassium ions and G-quadruplexinteractive agents, which stabilize G-quadruplex structures, had an inhibitory effect on NDPK-B DNA binding activity. Based on our studies, we have proposed a stepwise trapping-out of the NHE III1 region in a single-stranded form, thus allowing singlestranded transcription factors to bind and activate c-myc transcription. This model provides a rationale for how the stabilization of G-quadruplexes within the c-myc gene promoter region can inhibit NDPK-B from activating c-myc transcription. Similarly, the human bcl-2 gene contains a GC-rich region within its promoter region, which is critical in the regulation of bcl-2 expression. We demonstrate that the guanine rich strand within this region can form three intramolecular G-quadruplex structures. Based on NMR studies, the central G-quadruplex forms a mixed parallel/antiparallel structure with three tetrads connected by loops of one, seven, and three bases. The Gquadruplex structures in the bcl-2 promoter extends beyond the ability to form any one of three separate G-quadruplexes to each having the capacity to form either three or six different loop isomers. This suggests that targeting these individual structures could lead to different biological outcomes. We also found that Telomestatin upregulates bcl-2 gene expression, which we propose is a result of inhibiting the binding of the WT1 repressor protein by the formation of a drug-stabilized G-quadruplex structure.

The activated product of the c-MYC proto-oncogene is one of the strongest known activators of carcinogenesis. It has been estimated that as many as one-seventh of all cancer deaths are associated with alterations in the c-MYC gene or its expression [1]. Therefore, understanding the regulation of c-MYC expression is a key factor in understanding carcinogenesis in many histologic classes of malignancy. The nuclease hypersensitive element (NHE) III₁ region of the c-MYC promoter has been shown to be particularly important in regulating c-MYC expression. Specifically, the formation of a G-quadruplex structure appears to promote repression of c-MYC transcription. In this dissertation, we investigate the role that nucleolin, a critical player in ribosome biogenesis and cell stress sensing, plays on the transcriptional regulation of the c-MYC promoter through its interaction with the c-MYC G-quadruplex structure. Our studies initiated with the design of a c-MYC G-quadruplex affinity column intended to trap potential c-MYC G-quadruplex-binding proteins that were then identified by LC-MS/MS. After careful examination of the literature of the list of potential c-MYC G-quadruplexbinding proteins, we realized that several of the proteins identified had been previously reported to interact directly with nucleolin. Consequently, we chose to focus our studies on nucleolin, as it could be a central regulator of the (NHE) III region. By performing chromatin immunoprecipitation in HeLa cells, we found that nucleolin indeed interacts with the c-MYC promoter region containing the NHE III₁ element. This binding activity was confirmed by both electromobility shift assay and polymerase stop assay. We provide evidence that nucleolin can induce the formation of the c-MYC G-quadruplex structure from single-stranded DNA, both in linear and circular DNA forms. We show that upon binding, nucleolin increases the stability of the c-MYC G-quadruplex structure leading to repression of c-MYC promoter activity. We also show that nucleolin binds with much higher affinity to G-quadruplex structures with topology similar to that of the parallel c-MYC G-quadruplex, such as those found in the VEGF and PDGF-A promoters; in comparison to G-quadruplexes found in telomeres or the c-MYB promoter, whose have significantly different topology. Interestingly, we also demonstrate that nucleolin binds with higher affinity to the c-MYC G-quadruplex than to its consensus RNA substrate, the nucleolin recognition element (NRE). Furthermore, we show that the C-terminal domain of nucleolin is critical for its interaction and stabilization of the c-MYC G-quadruplex structure. Lastly, we show that the binding of nucleolin to the (NHE) III region causes repression of c-MYC transcription. On the basis of these results, we propose that nucleolin may play an important role in the transcriptional regulation of c-MYC in vivo by inducing the formation of the c-MYC G-quadruplex structure.

5 Abstract Neuroblastoma is one of the most common cancer diseases diagnosed in children. This rapidly growing solid tumor is usually formed by hypoxic areas which arise as a consequence of inefficient and disorganized neovascularization. The cells stressed by hypoxia triggers transcription of many genes necessary for their survival, and conversely stop the production of proteins which are not necessarily needed for the survival in these severe conditions. The adaptation of cells to hypoxic conditions may appear due to the epigenetic regulation of metabolism associated with chromatin remodeling which involves the DNA methylation and also the posttranslational modifications of histones. Among the most important of these, there is the acetylation of lysine residues of histones associated with the DNA strands loosening, facilitated binding of transcription factors and the activation of gene expression. Thus, the first part of this study is concerned with changes in the acetylation of histones H3 and H4 of human neuroblastoma cell lines UKF-NB-3, UKF-NB-4, SH-SY5Y and SK-N-AS, cultured in parallel under standard culture conditions and in the absence of oxygen (hypoxia, 1% O2) for 24 hours, which are studied by Western blot analysis. Thereupon, the activity of histone deacetylases and histonacetyltransferases,...

Many pathways dysregulated in prostate cancer are also involved in epithelial differentiation. To better understand prostate tumor initiation, we sought to investigate specific genes and mechanisms required for normal basal to luminal cell differentiation. Utilizing human prostate basal epithelial cells and an in vitro differentiation model, we tested the hypothesis that regulation of NOTCH3 by the p38 MAPK family (hereafter p38-MAPK), via MYC, is required for luminal differentiation. Inhibition (SB202190 and BIRB796) or knockdown of p38a (also known as MAPK14) and/or p38d (also known as MAPK13) prevented proper differentiation. Additionally, treatment with a gamma-secretase inhibitor (RO4929097) or knockdown of NOTCH1 and/or NOTCH3 greatly impaired differentiation and caused luminal cell death. Constitutive p38-MAPK activation through MKK6(CA) increased NOTCH3 (but not NOTCH1) mRNA and protein levels, which was diminished upon MYC inhibition (10058-F4 and JQ1) or knockdown. Furthermore, we validated two NOTCH3 enhancer elements through a combination of enhancer (e) RNA detection (BruUV-seq) and luciferase reporter assays. Finally, we found that the NOTCH3 mRNA half-life increased during differentiation or upon acute p38-MAPK activation. These results reveal a new connection between p38-MAPK, MYC and NOTCH signaling, demonstrate two mechanisms of NOTCH3 regulation and provide evidence for NOTCH3 involvement in prostate luminal cell differentiation.

No description available.

Introduction: Hearing loss affects over 500 million people worldwide and results from irreversible damage to inner ear hair cells. The only available treatment is cochlear implants, which may be unable to provide sensory input if neuronal connections are lost, as they are in mouse models. Thus, regeneration of hair cells offers the only permanent cure; however, such therapeutic intervention requires a detailed molecular understanding inner ear development and hair cell maintenance. During mouse development, there is a balance between proliferation and differentiation that not only determines the size of the ear, but also is needed to form a functional sensory unit. The fulcrum to this balance is N-Myc, a key transcription factor that acts as a node incorporating many upstream growth signaling pathways and funnels them to directly alter the cell cycle and at the same time inhibits differentiation. The loss of N-Myc results in major morphogenetic abnormalities, including a progressive loss of cochlear, despite their initial formation. Interestingly, N-Myc is present in inner ear hair cells after birth, long after proliferation in the inner ear ceased. In addition to N-Myc, L-Myc is co-expressed throughout development in the inner ear. This data suggests that N-Myc and L-Myc may play partially redundant roles both early during development and later in hair cells. Elucidating the relative importance of the Mycs and their interdependent roles in maintaining the balance between proliferation and differentiation may shed light on future hair cell regeneration avenues. Methods: We generated two Cre-LoxP lines, knocking out both N-Myc and L-Myc before (Pax2-Cre) and after (Atoh1-Cre) hair cell formation. We assessed the possibility of Myc redundancy through 3D reconstructions generated from confocal image stacks from E10.5-E18.5 and the effects of early Myc loss on the balance between proliferation and differentiation through a quantitative PCR study that assessed relative changes in gene expression, using the Pax2-Cre N-Myc f/f L-Myc f/f mice. We assessed organ of Corti development and functionality at P21 and four months of age in the Atoh1-Cre N-Myc f/f L-Myc f/f mice. Results: The development of the Pax2-Cre N-Myc f/f L-Myc f/f mutant ear was more severely impacted than the Pax2-Cre N-Myc f/f alone, as shown by an additional 50% reduction in size. Genes important to cell cycle maintenance were downregulated whereas differentiation transcription factors were initially downregulated but subsequently later upregulated to normal levels. In Atoh1-Cre N-Myc f/f L-Myc f/f mice, there were no defects in hair cell development. Discussion: There appears to be redundancy between N-Myc and L-Myc with N-Myc playing a more important role in inner ear formation. The late-onset defects seen in the Pax2-Cre N-Myc f/f mice appear to be a result of abnormal formation of hair cells due to the disruption in the balance between proliferation and differentiation much earlier on. This is the first time such a late-onset hair cell loss has been shown to be due to a defect sustained much earlier and is an important finding as the majority of people suffer from late-onset hearing loss. Additionally, these findings highlight the continued therapeutic importance in elucidating the molecular interactions controlling the delicate shift from a proliferating precursor to a differentiating cell.